This review aims to summarize the reported data on combined radiotherapy delivered, either concomitantly or sequentially, to both passive and active immune therapies for the treatment of HER2+ breast cancer, either in adjuvant or metastatic settings. Here, ERBB2 is linked to breast cancer.